نتایج جستجو برای: dlbcl lymphoma

تعداد نتایج: 102737  

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2010
N Niitsu M Okamoto J-i Tamaru T Yoshino N Nakamura S Nakamura K Ohshima H Nakamine M Hirano

BACKGROUND CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10% of DLBCLs, and it is associated with poor prognosis. The clinicopathologic characteristics and prognosis of CD5-negative (CD5-) DLBCL and CD5+ DLBCL were compared. PATIENTS AND METHODS The subjects were 607 DLBCL patients in whom cell surface markers could be analyzed, among 930 consecutive patients registered...

2015
Camille Laurent Konstantina Charmpi Pauline Gravelle Marie Tosolini Camille Franchet Loïc Ysebaert Pierre Brousset Alexandre Bidaut Bernard Ycart Jean-Jacques Fournié

Follicular Lymphomas (FL) and diffuse large B cell lymphomas (DLBCL) must evolve some immune escape strategy to develop from lymphoid organs, but their immune evasion pathways remain poorly characterized. We investigated this issue by transcriptome data mining and immunohistochemistry (IHC) of FL and DLBCL lymphoma biopsies. A set of genes involved in cancer immune-evasion pathways (Immune Esca...

2016
Sandra Sunitsch Magdalena Gilg Karl Kashofer Andreas Leithner Bernadette Liegl-Atzwanger Christine Beham-Schmid

BACKGROUND Primary bone lymphomas (PBL) are extremely rare malignant neoplasms. The most commonly described subtype of PBL is diffuse large B-cell lymphoma (DLBCL). DLBCL within peri-prosthetic membrane of a joint is exceedingly rare. To the best of our knowledge this case is the second reported Epstein-Bar-Virus (EBV) negative DLBCL in a peri-prosthetic membrane in the literature. CASE PRESE...

2008
Beate Hauptrock Georg Hess

INTRODUCTION The use of rituximab has led to significant improvements in the outcome of both aggressive and indolent Non-Hodgkin's lymphoma (NHL). It is the first targeted therapy to be developed for the treatment of lymphoma which has been widely adopted. AREAS COVERED This paper discusses the use of rituximab in NHL, mainly concentrating on diffuse large B cell lymphoma (DLBCL) and follicul...

Journal: :Molecular cancer therapeutics 2012
Judy Quiju Shi Kerri Lasky Vaishali Shinde Bradley Stringer Mark G Qian Debra Liao Ray Liu Denise Driscoll Michelle Tighe Nestor Benjamin S Amidon Youlan Rao Matt O Duffey Mark G Manfredi Tricia J Vos Natalie D' Amore Marc L Hyer

Diffuse large B-cell lymphoma (DLBCL) is the most common of the non-Hodgkin lymphomas, accounting for up to 30% of all newly diagnosed lymphoma cases. Current treatment options for this disease are effective, but not always curative; therefore, experimental therapies continue to be investigated. We have discovered an experimental, potent, and selective small-molecule inhibitor of PLK1, MLN0905,...

2017
Z Lu C C Hong P C Jark A L F V Assumpção N Bollig G Kong X Pan

BACKGROUND Canine diffuse large B-cell lymphoma (DLBCL) is a common and aggressive hematologic malignancy. The lack of conventional therapies with sustainable efficacy warrants further investigation of novel therapeutics. The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways play important roles in the pathogenesis of hematologic malignancies in humans incl...

Journal: :Blood 2013
Shimin Hu Zijun Y Xu-Monette Aarthi Balasubramanyam Ganiraju C Manyam Carlo Visco Alexander Tzankov Wei-min Liu Roberto N Miranda Li Zhang Santiago Montes-Moreno Karen Dybkær April Chiu Attilio Orazi Youli Zu Govind Bhagat Kristy L Richards Eric D Hsi William W L Choi J Han van Krieken Qin Huang Jooryung Huh Weiyun Ai Maurilio Ponzoni Andrés J M Ferreri Xiaoying Zhao Jane N Winter Mingzhi Zhang Ling Li Michael B Møller Miguel A Piris Yong Li Ronald S Go Lin Wu L Jeffrey Medeiros Ken H Young

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic fact...

2018
Wei Liu Juan Chen Archito T. Tamayo Changgeng Ruan Li Li Shouhao Zhou Chan Shen Ken H. Young Jason Westin Richard E. Davis Shimin Hu Leonard J. Medeiros Richard J. Ford Lan V. Pham

Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed/refractory disease, particularly those with adverse genetic features (e.g., mutated p53 or double hit lymphoma (DHL)) have very poor prognoses, and effective therapies are lacking. In this study we examined the preclinical efficacy and associated biological effects of the ...

2012
Hiroshi Kazama Masanao Teramura Kentaro Yoshinaga Akihiro Masuda Toshiko Motoji

Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is a rare type of extranodal lymphoma with poor prognosis. Here, we report a case of primary bone marrow DLBCL successfully treated with high-dose chemotherapy and rescued by in vivo rituximab-purged autologous stem cells. A 39-year-old woman visited our hospital because of anemia. Bone marrow examination revealed a large B-cell lymphoma...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Kieron Dunleavy Mark Roschewski Wyndham H Wilson

Although diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, was once considered to be a single disease, novel insights into its biology have revealed that it is molecularly heterogeneous. Technologies such as gene expression profiling have revealed that DLBCL consists of at least three distinct molecular diseases that have disparate outcomes following standard ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید